|
Home
Services
Examples
From Portfolio
Contacting
Us
Comments
Links
|
Selected Publications &
Projects
Manuscripts
Slide Kits
Abstracts/Posters/Proceedings
Monographs
Web Writing
Patient
Education//Newsletters/Brochures
Sales Training
Manuscripts (to
top of page)
Diabetes
Guthrie R. Is there
a need for a better basal insulin? Clin
Diabetes 2001;19:66-70.
Ratner R, et al. Less hypoglycemia with
insulin glargine in intensive insulin therapy for type 1 diabetes. Diabetes
Care 2000;23:639-43.
Campbell R. Glimepiride: role of a new
sulfonylurea in the treatment of type 2 diabetes mellitus. Ann Pharmacother
1998;32:1044-52.
Respiratory
Graft D, et al. Safety of
fexofenadine HCl in children treated for seasonal allergic rhinitis. Ann
Allergy Asthma Immunol 2001;87:22-6.
Thompson A, et al. Effect
of 60 mg BID fexofenadine HCl on quality of life, work and classroom
productivity, and regular activity in patients with chronic idiopathic
urticaria. J Am Academy Derm 2000;43:24-30.
Thompson A, et al.
Quality of life in patients with allergic rhinitis. Ann Allergy Asthma
Immunol 2000;85:338-47. (CME).
Schoenwetter W. Allergic
rhinitis: epidemiology and natural history. Allergy Asthma Proc
2000;21:1-6.
Philpot E. Safety of
second generation antihistamines. Allergy Asthma Proc 2000;21:15-20.
Blaiss M. Cognitive,
social, and economic costs of allergic rhinitis. Allergy Asthma Proc
2000;21:7-13.
Nelson H, et al.
Fexofenadine HCl is safe and effective for treatment of chronic idiopathic
urticaria. Ann Allergy Asthma Immunol 2000;84:517-22.
Tanner A, et al.
Effective of fexofenadine HCl on quality of life and work, classroom, and
daily activity impairment in patients with seasonal allergic rhinitis. Am J
Managed Care 1999;5:S235-47.
Meltzer E., et al.
Once-daily fexofenadine HCl improves quality of life and reduces work and
activity impairment in patients with seasonal allergic rhinitis. Ann
Allergy Asthma Immunol 1999;83:311-7.
Casale,T, et al. Safety
and efficacy of once-daily fexofenadine HCl in the treatment of autumn
seasonal allergic rhinitis. Allergy and Asthma Proc 1999;20:193-8.
Pratt C, et al.
Cardiovascular safety of fexofenadine HCl. Am J Cardiol 1999;83:1451-4.
Finn A, et al. A
double-blind, placebo-controlled trial of fexofenadine HCl in the treatment of
chronic idiopathic urticaria. J Allergy Clin Immunol 1999:104;1071-8.
Bronsky E, et al.
Effectiveness and safety of Fexofenadine, a new nonsedating H1-receptor
antagonist, in the treatment of fall allergies. Allergy Asthma Proc
1998;19:135-41.
Bernstein D, et al.
Efficacy and safety of fexofenadine hydrochloride for treatment of seasonal
allergic rhinitis. Ann Allergy Asthma Immunol 1997;79:443-8.
Osteoporosis
Raisz L., et al. Short-term risedronate treatment
in postmenopausal women: effects on biochemical markers of bone turnover.
Osteoporos Int 2000;11:615-20.
Lambing C. Osteoporosis
prevention, detection, and treatment: a mandate for primary care. Postgrad
Med 2000;107:37-56. (CME).
Brown J, et al.
Improvement of pagetic bone lesions with risedronate treatment: A radiographic
study. Bone 2000;26:263-7.
Hematology
Greinacher A, et al.
Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients
with heparin-induced thrombocytopenia. Circulation 1999;100:587-93.
Greinacher A, et al.
Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in
patients with heparin-induced thrombocytopenia. Circulation
1999;99:73-80.
Eichler P, et al. First
workshop for detection of heparin-induced antibodies: validation of the
heparin-induced platelet-activation test (HIPA) in comparison with a
PF4/heparin ELISA. Thromb Haemost 1999;81:625-9.
Carlsson L, et al. The
a2
gene coding sequence T807/A873 of the platelet collagen
receptor integrin
a2b1
might be a genetic risk factor for the development of stroke in younger
patients. Blood 1999;93:3583-86.
Carlsson L, et al. Heparin-induced
thrombocytopenia: new insights into the impact of the FcgRIIa-R-H131
polymorphism. Blood 1998;92:1526-31.
Olbrich K, et al.
Atypical heparin-induced thrombocytopenia complicated by intracardiac
thrombus, effectively treated with ultra-low-dose rt-PA lysis and recombinant
hirudin (Lepirudin). Blood Coagul Fibrin 1998;9:273-7.
Krantz SR, et al. A
retrospective analysis of a formulary transition at a large metropolitan HMO:
Nifedipine GITS to felodipine ER. J Managed Care Pharm
1996;2:642-6.
Cardiovascular
Piepho RW. Calcium antagonist use in congestive
heart failure: still a bridge too far? J Clin Pharmacol 1995;35(5):443-453.
Krantz SR, Rase RS, Piepho RW. A retrospective
analysis of a formulary transition at a large metropolitan HMO: nifedipine
GITS to felodipine ER. J Managed Care Pharm 1996;2:642-646.
Oncology
Philip B, et al. Pooled analysis of three
large clinical trials to determine the optimal dose of dolasetron mesylate
needed to prevent postoperative nausea and vomiting. J Clin Anesth
2000;12:1-8.
Whitmore J, et al. Rationale for the use of a
single fixed intravenous dolasetron dose for the prevention of cisplatin-induced
nausea and vomiting. Support Care Cancer 1998;6:473-8.
Diemunsch P, et al. Oral dolasetron mesylate
for prevention of postoperative nausea and vomiting: a multicenter,
double-blind, placebo-controlled-study. J Clin Anesth 1998;10:145-52.
Kortilla K, et al. Intravenous dolasetron and
ondansetron in prevention of postoperative nausea and vomiting: a multicenter
double-blind, placebo-controlled study. Acta Anaesthesiol Scand
1997;41:1-9.
Kovac A, et al. Treatment of postoperative
nausea and vomiting with single intravenous doses of dolasetron mesylate: a
multicenter trial. Anesth Analg 1997;85:546-52.
Grote TH, et al. Oral dolasetron mesylate in
patients receiving moderately emetogenic platinum-containing chemotherapy.
Cancer J 1997;3:45-51.
Rubenstein EB, et al.
Randomized, double blind, dose-response trial across four oral doses of
dolasetron for the prevention of acute emesis after moderately emetogenic
chemotherapy. Cancer 1997;79:1217-24.
Bey
P, et al. A double-blind, placebo-controlled trial of i.v. dolasetron mesylate
in the prevention of radiotherapy-induced nausea and vomiting in cancer
patients. Support Care Cancer 1996;4:378-83.
Benedict CR, et al. Single-blind study of the effects of intravenous
dolasetron mesylate versus ondansetron on electrocardiographic parameters in
normal volunteers. J Cardiovasc Pharm. 1996;28:53-9.
Hesketh P, et al. Double-blind, randomized comparison of
the antiemetic efficacy of intravenous dolasetron mesylate and intravenous
ondansetron in the prevention of acute cisplatin-induced emesis in patients
with cancer. J Clin Oncol 1996;14(8):2242-9.
Fauser AA, et al. A double-blind, randomized, parallel study of IV dolasetron
mesylate versus IV metoclopramide in patients receiving moderately emetogenic
chemotherapy. Cancer J 1996;9:196-202.
Bey P, Wilkinson PM, Resbeut M, et al.
A double-blind, placebo-controlled trial of i.v. dolasetron mesylate in
the prevention of radiotherapy-induced nausea and vomiting in cancer patients.
Support Care Cancer 1996;4:378-383.
Benedict CR, Arbogast R, Martin L, et al.
Single-blind study of the effects of intravenous dolasetron mesylate versus
ondansetron on electrocardiographic parameters in normal volunteers. J
Cardiovasc Pharm. 1996;28:53-59.
Hesketh P, Navari R, Grote, T, et al. Double-blind,
randomized comparison of the antiemetic efficacy of intravenous dolasetron
mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced
emesis in patients with cancer. J Clin Oncol 1996;14(8):2242-2249.
Smoking Cessation
Joslin KA, Fleszar GJ, Malone NT, et al.
Report of two smoking cessation programs: telephone intervention and
group sessions. HMO Pract 1995;9(3):134-137.
Legorreta AP, Kashian C. Results of a unique,
cost-effective smoking cessation program in a managed care setting.
Am J Managed Care 1996. In press.
Richmond RL, Kehoe L, de Almeida Neto AC.
Effectiveness of a 24-Hour transdermal nicotine patch in conjunction with
a cognitive behavioral program: one year outcome. Addiction 1997;92:27-31.
Slide Kits
(to top of page)
Insulin Glargine Data
Slide Kit
Glimepiride Consultant's
Slide Kit
Insulin Glargine: Mode
of Action
Fexofenadine
Consultant's Slide Kit
Glimepiride: Mode of
Action
Antihistamine Driving Study
Chronic Stable Angina: Current Trends in
Diagnosis and Management
Cardiovascular Care for Hispanic Patients
Once-a-Day Cardizem CD®:
Controlled Diffusion Capsules for Hypertension
Seldane® Cardiovascular Safety
Cardizem Lyo-Ject for Bolus
Over 80 individual slide
presentations from articles, abstracts, and posters.
Abstracts/Posters/Proceedings
(to top of page)
Over 160 abstracts,
posters, and meeting proceedings.
Monographs (to top of page)
Lantus®
(insulin glargine) product monograph
Arava®
(leflunomide) product monograph
Lescol® (fluvastatin): Issues in Cholesterol Therapy
National Association of Retail Druggists: Ideas to Improve Your Pharmacy
Practice
Review of
Seldane Cardiovascular Safety White Paper
Web-Specific Writing
(to top of page)
Wrote content for
the Prozac website, www.prozac.com (Feb,
2000)
Patient Education/Newsletters/Brochures
(to top of page)
The Lipid Link: A quarterly newsletter for cardiovascular nurses
about the treatment of lipid disorders
Heart Edge: Newsletter for cardiovascular sales representatives
Corporate Advisory Board newsletter
Physician Advisory Board
newsletter
Sales Training (to top of page)
Pentasa® Patient Education Booklet
Gastrointestinal Primer
Carafate® Sales Training Manual
CAMP: An Account Management Process
|